Johnson & Johnson (JNJ)

👁 What to Watch

• Q2 2026 results — key test of whether Stelara erosion is running below or above guidance; watch for Darzalex/Tremfya offset confirmation and MedTech momentum
• Firefly Bio close and Halda integration — early commentary on timeline and pipeline progress at Halda's RIPTAC and Firefly's Firelink platforms
• Stelara biosimilar market share data — quarterly monitoring of market penetration to assess speed of revenue erosion vs. analyst models
• Ottava robotic surgery commercial launch — after meeting primary clinical endpoints in gastric bypass study, watch for regulatory filing timing
• Talc litigation developments — any material settlement news or unfavourable court rulings could move the financial overhang estimate
• Debt trajectory and leverage — with net cash now restored, watch whether any larger acquisitions change the balance sheet profile

J&J's financial health is strong overall. The Z-Score of 4.37 places the company firmly in the Safe Zone — very low bankruptcy risk. The company is in a net cash position (Net Debt/EBITDA -0.1x) following the resolution of near-term acquisition financing. Interest coverage stands at 24.8x, demonstrating substantial debt service capacity relative to operating profits. Debt/equity is minimal at 0.7%.

The F-Score of 6/9 reflects a good but not exceptional fundamental momentum picture. Positive signals: ROA is positive, operating cash flow is positive and strong, earnings quality is high (OCF at 0.92x net income), long-term debt has decreased year-on-year, and gross margin and asset turnover are both improving. Negative signals: ROA declined slightly YoY (acquisitions absorbing asset base faster than returns are building); current ratio fell from 1.26 to 1.03 (working capital position tightening); and shares outstanding edged up (modest dilution from equity compensation). The current ratio of 1.03 and quick ratio of 0.77 are weak in absolute terms but not alarming for a mega-cap with ready capital market access and USD 22.9B operating cash flow annually.

Goodwill and intangibles represent 40.4% of total assets — elevated but declining from a peak of over 50% historically as the acquired-asset base is amortised. The two recent acquisitions (Halda, Firefly Bio) will modestly increase this ratio before it resumes declining. OCF/Net Income of 0.92x confirms that reported earnings are backed by real cash generation.

J&J's profitability profile is among the highest-quality in global large-cap healthcare. Gross margin of 72.8% reflects the premium positioning of pharmaceutical innovation and the structural uplift from removing the lower-margin consumer business via the Kenvue separation. Operating margin of 27.2% is strong for a company at this scale with significant R&D investment. Net margin of 28.5% and ROCE of 23.1% confirm the durability of returns.

FCF margin of 20.9% — generating c. USD 20B of free cash flow on USD 96B of revenue — is the metric that underpins the dividend, the buyback programme, and the capacity for bolt-on acquisitions without materially stretching the balance sheet. ROE of 32.9% reflects the compound effect of high margins and efficient asset utilisation. ROA of 13.5% is solid, though it modestly declined YoY as the recent acquisitions absorb capital ahead of their full earnings contribution.

The 2025 margin expansion from 69.1% to 72.8% gross margin is the most notable recent development — the Kenvue separation effect fully flowing through the income statement. Management's guidance of USD 100.8B in 2026 revenue with adj. EPS $11.55 implies continued margin discipline even with Stelara headwinds and acquisition dilution.

Revenue growth has re-accelerated: 1Y +6.0%, 3Y +5.6% CAGR, 5Y +2.7% CAGR (the 5Y figure reflects the consumer mix during the Kenvue years). Q1 2026 delivered +9.9% reported growth — ahead of the long-run trend — driven by accelerating Innovative Medicine (Darzalex +22.5%, Tremfya +68.3%) offset partially by Stelara erosion.

Earnings growth of +90.6% in FY2025 is eye-catching but primarily a normalisation: FY2024 net income was suppressed by talc litigation charges. On an underlying basis, earnings compounding is in the 5-8% range. FCF has been broadly stable over five years (2021-2025: USD 19.8B to USD 19.7B), reflecting the absorption of higher acquisition-related capex and working capital changes rather than any deterioration in cash conversion quality. Management's 2026 guidance of adj. EPS $11.55 implies 7% EPS growth — consistent with the medium-term compounding rate.

The pipeline build via Halda and Firefly Bio extends the decade-long growth runway in oncology — the segment of the pharmaceutical market with the highest pricing power and greatest unmet need. These are pre-revenue platform acquisitions; their value is in the 2028+ growth optionality rather than near-term earnings contribution.

Valuation is the dominant constraint on the investment case and the reason the Spriggl algorithmic score of 53 sits in the Moderate band despite excellent business quality scores. At current levels, the stock trades at trailing P/E 26.5x, EV/EBITDA 17.3x, and Price/FCF 30.9x — all in expensive territory for an established mega-cap growing at 5-7% per annum. The earnings yield of 3.8% compares unfavourably with current risk-free rates, though the progressive dividend and quality of earnings provide a premium argument.

Analyst consensus is broadly constructive: 7 Strong Buy, 4 Buy, 13 Hold (24 total coverage). The median price target of USD 253 implies about +9.8% upside from the current price near USD 230 — a positive but modest return expectation for a premium valuation. Forward P/E of 19.9x (on FY2026 adj. EPS of $11.55) is more palatable and implies the market is effectively paying a control premium for certainty of execution. The PEG ratio of 2.97 is elevated, confirming that the valuation requires sustained above-average execution to justify.

The AI Score of 72 (Strong) weights the business quality and dividend trajectory more heavily than the pure algorithmic value assessment — reflecting the judgment that a franchise of this depth warrants a quality premium, even if the near-term total return from the current price is likely modest.

Johnson & Johnson's dividend is one of the most reliable in global equity markets. The company has raised its quarterly distribution for 64 consecutive years — achieving Dividend King status — with the most recent increase of 3.1% announced in April 2026, lifting the quarterly payout to $1.34 per share (USD 5.36 annualised). The 5-year dividend CAGR of 5.2% has been consistent and above inflation.

Dividend sustainability is robust. Annual FCF of c. USD 20B comfortably covers the annual dividend bill (estimated c. USD 13B at current per-share rate and share count), leaving meaningful surplus for acquisitions and buybacks. The payout ratio of 51.5% is moderate — appropriate for a company reinvesting heavily in pipeline development and acquisitions. The Dividend Health score of 56/100 reflects a sound but not exceptional picture: the yield at 2.28% is modest relative to sector income funds, and the dividend is growing at a rate that requires sustained earnings compounding to maintain the trajectory.

DPS trajectory over five years: $4.19 (2021), $4.45 (2022), $4.70 (2023), $4.91 (2024), $5.14 (2025), now increasing to $5.36 annualised (2026). For income-focused investors, the dividend growth trajectory — rather than the current yield — is the primary attraction.

📰 Latest News